Articles dans des revues avec comité de lecture (396)
  1. 313. Strumberg, D., Awada, A., Hirte, H. W., Clark, J. W., Seeber, S., Piccart, P., Hofstra, E., Voliotis, D., Christensen, O., Brueckner, A., & Schwartz, B. (2006). Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? European journal of cancer, 42(4), 548-556. doi:10.1016/j.ejca.2005.11.014
  2. 314. Lalami, Y., Gil, T., D'Hondt, V., Piccart-Gebhart, M., & Awada, A. (2006). Cancer du rein: de la biologie a la clinique. Revue médicale suisse, 2(55), 600-4, 606-8.
  3. 315. Lothaire, P., de Azambuja, E., Dequanter, D., Lalami, Y., Sotiriou, C., Andry, G., Castro, G., & Awada, A. (2006). Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head & neck, 28(3), 256-269. doi:10.1002/hed.20326
  4. 316. Siu, L. L., Awada, A., Takimoto, C. H., Piccart-Gebhart, M., Schwartz, B., Giannaris, T., Lathia, C., Petrenciuc, O., & Moore, M. J. (2006). Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clinical cancer research, 12(1), 144-151. doi:10.1158/1078-0432.CCR-05-1571
  5. 317. Tirelli, U., de Castro, G., & Awada, A. (2006). Keynote comment: reimbursement for molecularly targeted anticancer agents. Lancet oncology, 7(1), 2-3. doi:10.1016/S1470-2045(05)70512-X
  6. 318. Bernard, C., Lebrun, F., Awada, A., & Piccart-Gebhart, M. (2006). Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs, 66(12), 1577-1591.
  7. 319. Vereecken, P., Zouaoui Boudjeltia, K., Debray, C., Awada, A., Legssyer, I., Sales, F., Petein, M., Vanhaeverbeek, M., Ghanem, G. E., & Heenen, M. (2006). High serum galectin-3 in advanced melanoma: preliminary results. Clinical and experimental dermatology, 31(1), 105-109. doi:10.1111/j.1365-2230.2005.01992.x
  8. 320. Korri, H., & Awada, A. (2005). Effets indésirables hépatiques graves sous tolcapone survenus 17 mois après le début du traitement. Revue neurologique, 161(11), 1113-1115.
  9. 321. D'Hondt, V., Gil, T., Lalami, Y., Piccart-Gebhart, M., & Awada, A. (2005). Will the dark sky over advanced renal cell carcinoma soon become brighter? European journal of cancer, 41(9), 1246-1253. doi:10.1016/j.ejca.2004.11.025
  10. 322. Awada, A., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M. S., de Valeriola, D., Strumberg, D., Brendel, E., Haase, C. G., Schwartz, B., & Piccart-Gebhart, M. (2005). Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. British Journal of Cancer, 92(10), 1855-1861. doi:10.1038/sj.bjc.6602584
  11. 323. Awada, A., & Lalami, Y. (2005). Molecular markers, molecular-targeted therapies and taxanes: how to integrate the progress into clinical research and practice for the management of head and neck cancers. Current opinion in oncology, 17(3), 209-211. doi:10.1097/01.cco.0000156984.81195.46
  12. 324. Awada, A., & Torti, F. F. (2005). Editorial introductions. Current opinion in oncology, 17(3), i-ii. doi:10.1097/00001622-200505000-00001
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>